- Home
- SPT vs MNPR Comparison
SPT vs MNPR Comparison
Compare SPT & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPT | MNPR |
|---|---|---|
| Founded | 2010 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 633.9M | 531.6M |
| IPO Year | 2019 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SPT | MNPR |
|---|---|---|
| Price | $10.61 | $67.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 13 |
| Target Price | $26.00 | ★ $97.83 |
| AVG Volume (30 Days) | ★ 983.9K | 263.6K |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $443,750,000.00 | N/A |
| Revenue This Year | $13.30 | N/A |
| Revenue Next Year | $11.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.09 | N/A |
| 52 Week Low | $9.16 | $21.00 |
| 52 Week High | $35.18 | $105.00 |
Technical Indicators
Market Signals| Indicator | SPT | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 44.52 | 40.10 |
| Support Level | $10.97 | $63.73 |
| Resistance Level | $11.63 | $74.34 |
| Average True Range (ATR) | 0.48 | 4.32 |
| MACD | -0.03 | -0.34 |
| Stochastic Oscillator | 16.51 | 27.48 |
Price Performance
Historical ComparisonAbout SPT Sprout Social Inc
Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.